Insmed | INSM - Operating Expenses

Stock Price
144.54
Daily Change
5.04 3.61%
Monthly
-3.97%
Yearly
85.86%
Q1 Forecast
135.29

Insmed reported $513.55M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 513.55M 109.86M Dec/2025
Novartis USD 9.77B 401M Sep/2025
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025